A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2489-2497

  Yuan, Shuofeng ^a   Chu, Hin ^a   Zhang, Ke ^a   Ye, Jiahui ^a   Singh, Kailash ^b   Kao, Richard Y T ^a   Chow, Billy K C ^b   Zhou, Jie ^a   Zheng, Bo Jian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CAP BINDING PROTEIN; PB2 PROTEIN, INFLUENZA VIRUS; VIRAL PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL LINE; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; FLUORESCENCE POLARIZATION; HUMAN; INFLUENZA A VIRUS; ISOLATION AND PURIFICATION; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; TREATMENT OUTCOME; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; FLUORESCENCE POLARIZATION; HUMANS; INFLUENZA A VIRUS; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RNA CAP-BINDING PROTEINS; TREATMENT OUTCOME; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 85017134531     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw194     Document Type: Article

References (35)

1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-15.
2. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368: 1888-97.
3. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007; 20: 243-67.
4. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis 2006; 12: 55-60.
5. Bright RA, Shay DK, Shu B et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 891-4.
6. Hai R, Schmolke M, Leyva-Grado VH et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4: 2854.
7. Thorlund K, Awad T, Boivin G et al. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011; 11: 134.
8. Boivin S, Cusack S, Ruigrok RWet al. Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms. J Biol Chem 2010; 285: 28411-7.
9. Reich S, Guilligay D, Pflug A et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 2014; 516: 361-6.
10. Guilligay D, Tarendeau F, Resa-Infante P et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 2008; 15: 500-6.
11. Yanguez E, Rodriguez P, Goodfellow I et al. Influenza virus polymerase confers independence of the cellular cap-binding factor eIF4E for viral mRNA translation. Virology 2012; 422: 297-307.
12. Liu Y, Qin K, Meng G et al. Structural and functional characterization of K339 T substitution identified in the PB2 subunit cap-binding pocket of influenza A virus. J Biol Chem 2013; 288: 11013-23.
13. Pautus S, Sehr P, Lewis J et al. New7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain. J Med Chem 2013; 56: 8915-30.
14. Clark MP, Ledeboer MW, Davies I et al. Discovery of a novel, first-inclass, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 2014; 57: 6668-78.
15. Hsu JT, Yeh JY, Lin TJ et al. Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus. Antimicrob Agents Chemother 2012; 56: 647-57.
16. Byrn RA, Jones SM, Bennett HB et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 2015; 59: 1569-82.
17. Lea WA, Simeonov A. Fluorescence polarization assays in small molecule screening. Expert Opin Drug Discov 2011; 6: 17-32.
18. Baughman BM, Jake Slavish P, DuBois RM et al. Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS Chem Biol 2012; 7: 526-34.
19. Cho EJ, Xia S, Ma LC et al. Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay. J Biomol Screen 2012; 17: 448-59.
20. Kao RY, Yang D, Lau LS et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 2010; 28: 600-5.
21. Zheng B, Chan KH, Zhang AJ et al. D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med (Maywood) 2010; 235: 981-8.
22. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105: 8091-6.
23. Zheng BJ, Ng MH, He LF et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 2001; 19: 4219-25.
24. Visco C, Perrera C, Thieffine S et al. Development of biochemical assays for the identification of eIF4E-specific inhibitors. J Biomol Screen 2012; 17: 581-92.
25. Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363: 617-9.
26. Yuan S, Chu H, Zhao H et al. Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Res 2016; 125: 34-42.
27. Schneidman-Duhovny D, Inbar Y, Nussinov R et al. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 2005; 33: W363-7.
28. Mashiach E, Schneidman-Duhovny D, Andrusier N et al. FireDock: aweb server for fast interaction refinement in molecular docking. Nucleic Acids Res 2008; 36: W229-32.
29. Hsu KC, Chen YF, Lin SR et al. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and postscreening analysis. BMC Bioinformatics 2011; 12 Suppl 1: S33.
30. Taylor RM. Experimental infection with influenza A virus in mice: the increase in intrapulmonary virus after inoculation and the influence of various factors thereon. J Exp Med 1941; 73: 43-55.
31. Smee DF, von Itzstein M, Bhatt B et al. Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrob Agents Chemother 2012; 56: 6328-33.
32. Judd AK, Sanchez A, Bucher DJ et al. In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob Agents Chemother 1997; 41: 687-92.
33. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007; 6: 967-74.
34. Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 312: 389-91.
35. Neumann G, Brownlee GG, Fodor E et al. Orthomyxovirus replication, transcription, and polyadenylation. Curr Top Microbiol Immunol 2004; 283: 121-43.